Vertex registers Phase 1 drug interaction study for VX-407 with oral contraceptives

Vertex Pharmaceuticals has a new Phase 1 trial listed on ClinicalTrials.gov studying drug interactions between VX-407 and oral contraceptives.

• NCT07792408 is a Phase 1, open-label drug interaction study evaluating the effect of VX-407 on the pharmacokinetics of combined oral contraceptives, sponsored by Vertex Pharmaceuticals Incorporated.¹ The study is listed as recruiting, with an actual start date of 2026-09-01 and an estimated primary completion date of 2027-03-11. The condition listed is Autosomal Dominant Polycystic Kidney Disease (ADPKD), and enrollment is estimated at 148 participants.¹ The design includes up to four optional parts testing VX-407 alongside different contraceptive combinations: levonorgestrel/ethinyl estradiol (LNG/EE)¹, norgestimate/ethinyl estradiol (NGM/EE)¹, norethindrone/ethinyl estradiol (NET/EE)¹, and drospirenone/ethinyl estradiol (DRSP/EE)¹. Primary outcomes focus on maximum plasma concentration and area under the concentration curve for each contraceptive component, with Part B measuring norelgestromin (NGMN) and norgestrel (NG), the active metabolites of NGM, and EE¹.